Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.
de Claro RA, McGinn K, Kwitkowski V, Bullock J, Khandelwal A, Habtemariam B, Ouyang Y, Saber H, Lee K, Koti K, Rothmann M, Shapiro M, Borrego F, Clouse K, Chen XH, Brown J, Akinsanya L, Kane R, Kaminskas E, Farrell A, Pazdur R. de Claro RA, et al. Among authors: mcginn k. Clin Cancer Res. 2012 Nov 1;18(21):5845-9. doi: 10.1158/1078-0432.CCR-12-1803. Epub 2012 Sep 7. Clin Cancer Res. 2012. PMID: 22962441
FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia.
de Claro RA, McGinn KM, Verdun N, Lee SL, Chiu HJ, Saber H, Brower ME, Chang CJ, Pfuma E, Habtemariam B, Bullock J, Wang Y, Nie L, Chen XH, Lu DR, Al-Hakim A, Kane RC, Kaminskas E, Justice R, Farrell AT, Pazdur R. de Claro RA, et al. Clin Cancer Res. 2015 Aug 15;21(16):3586-90. doi: 10.1158/1078-0432.CCR-14-2225. Clin Cancer Res. 2015. PMID: 26275952
The future of child and adolescent clinical psychopharmacology: A systematic review of phase 2, 3, or 4 randomized controlled trials of pharmacologic agents without regulatory approval or for unapproved indications.
Cortese S, McGinn K, Højlund M, Apter A, Arango C, Baeza I, Banaschewski T, Buitelaar J, Castro-Fornieles J, Coghill D, Cohen D, Grünblatt E, Hoekstra PJ, James A, Jeppesen P, Nagy P, Pagsberg AK, Parellada M, Persico AM, Purper-Ouakil D, Roessner V, Santosh P, Simonoff E, Stevanovic D, Stringaris A, Vitiello B, Walitza S, Weizman A, Wohlfarth T, Wong ICK, Zalsman G, Zuddas A, Moreno C, Solmi M, Correll CU. Cortese S, et al. Among authors: mcginn k. Neurosci Biobehav Rev. 2023 Jun;149:105149. doi: 10.1016/j.neubiorev.2023.105149. Epub 2023 Mar 29. Neurosci Biobehav Rev. 2023. PMID: 37001575 Free article. Review.
Daily activity timing in the Anthropocene.
Gilbert NA, McGinn KA, Nunes LA, Shipley AA, Bernath-Plaisted J, Clare JDJ, Murphy PW, Keyser SR, Thompson KL, Maresh Nelson SB, Cohen JM, Widick IV, Bartel SL, Orrock JL, Zuckerberg B. Gilbert NA, et al. Among authors: mcginn ka. Trends Ecol Evol. 2023 Apr;38(4):324-336. doi: 10.1016/j.tree.2022.10.008. Epub 2022 Nov 16. Trends Ecol Evol. 2023. PMID: 36402653 Review.
Gender, social class, and women's employment.
McGinn KL, Oh E. McGinn KL, et al. Curr Opin Psychol. 2017 Dec;18:84-88. doi: 10.1016/j.copsyc.2017.07.012. Epub 2017 Jul 17. Curr Opin Psychol. 2017. PMID: 28866434 Review.
19 results